Bristol Myers Squibb

We’re honored to share that Greg Meyers, EVP, Chief Digital & Technology Officer has been named to Forbes’ 2024 CIO Next List. As AI and machine learning continue to transform the future of healthcare, Greg has been instrumental in steering how our company leverages these advanced technologies to accelerate our scientific pursuits, empower our employees to do their best work, and deliver for our patients around the world. https://bit.ly/491C47y #OneBMS

We are committed to advancing research in cardiovascular diseases. Learn more about our ongoing trials in hypertrophic cardiomyopathy and other cardiovascular conditions on our website, BMS Clinical Trials. https://bit.ly/4fW39v0

We recently hosted an important discussion about breaking down barriers to healthcare access in low- and middle-income countries, known as LMICs. Together with the Union for International Cancer Control (UICC)’s ATOM Coalition and The Max Foundation, we’re focused on finding sustainable solutions, such as with the ASPIRE initiative, to ensure that every patient gets the care they need. #HealthEquity #GlobalHealth

This BMS Veteran and Military Appreciation Month, our Veterans Community Network (VCN) People & Business Resource Group (PBRG) hosted a Veterans Salute and fireside chat with U.S. Marine Sergeant Carlos Evans, his wife, Rosemarie, a nurse and advocate, and Samit Hirawat (he/him), Chief Medical Officer and Head of Development. See highlights from the event—held in partnership with our Disability Advancement Workplace Network and Organization for Latino Achievement PBRGs—and join us in celebrating the history and contributions of those who’ve served. Learn about VCN Global Lead, Ricardo Sanchez and how our VCN community promotes the success of veteran service members: https://bit.ly/4eCH3wJ #OneBMS

We are committed to advancing care for the Rheumatology community. Learn more about our ongoing clinical trials in lupus and Sjogren's disease, and other rheumatologic conditions at BMS Clinical Trials. https://bit.ly/3UUqbdW #OneBMS

We’re looking forward to presenting new data at the American Society of Hematology Annual Meeting and Exposition alongside thousands of healthcare professionals, researchers, industry peers and advocacy partners. Learn more about across our key research platforms, cell therapy and targeted protein degradation, at #ASH24: https://bit.ly/3Zei7Hx

Review the data and gain real-world insights from 22 months of a symptomatic obstructive HCM treatment in >6000 adult patients from our risk evaluation and mitigation strategy program. https://bit.ly/4eAKYtN #AHA2024

Explore the latest data on obstructive hypertrophic cardiomyopathy. Discover long-term safety and efficacy outcomes for a symptomatic obstructive HCM treatment on septal reduction therapy up to 128 weeks from the VALOR-HCM trial. https://bit.ly/48ZehFs #AHA2024

Our long-standing leadership in #CardiovascularDisease (CVD) and precision research approach drives our innovation to meet the needs of people with CVD. Learn more about our work to deliver paradigm-shifting medicines: https://bit.ly/3YWIOif #OneBMS

Through industry-leading discoveries and innovations, we're researching potential new treatments for those living with rheumatic diseases like #PsoriaticArthritis. In addition to experiencing loss of physical function, pain and fatigue, people living with psoriatic arthritis can face significant impacts to their mental and emotional well-being. We’re working to advance the science to not only address symptom management, but to increase rates of remission. https://bit.ly/4fxLgTt #ACR24 #OneBMS